Quarterly report · Q3
2914.TEDINET S100S3OU
Period2023-01-01 → 2023-09-30
Filed2023-10-31
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.16T | 2023-01-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥764.2bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥2.66T | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.01T | 2022-01-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥741.7bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥631.8bn | 2023-01-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥218.3bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥579.3bn | 2022-01-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥196.4bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥586.2bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥212.8bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥593.5bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥535.6bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥174.6bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥442.0bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥155.0bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥442.7bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥403.8bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥139.7bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥444.5bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥156.1bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥444.2bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥403.9bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥138.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥7.10T | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥6.55T | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥6.73T | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥3.10T | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.93T | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥4.00T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.62T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥3.87T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.89T | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥3.92T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥3.54T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥869.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥866.9bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥778.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥721.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥490.4bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥483.8bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥343.6bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥104.0bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥101.8bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥70.0bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥413.7bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥306.2bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥357.4bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥249.01 | 2023-01-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥87.31 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥249.45 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥227.53 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥78.74 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥248.95 | 2023-01-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥87.29 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥249.36 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥227.45 | 2022-01-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥78.71 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 55.2% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.1% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 56.3% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 136
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-09-30 | ¥3.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-07-01 → 2023-09-30 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-09-30 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-07-01 → 2023-09-30 | ¥488m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥2.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥652m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-09-30 | −¥30.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-09-30 | −¥30.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-09-30 | −¥18.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-07-01 → 2023-09-30 | −¥9.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-07-01 → 2023-09-30 | −¥9.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-07-01 → 2023-09-30 | ¥618m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-09-30 | −¥752m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-09-30 | −¥752m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-09-30 | ¥21m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-09-30 | ¥21m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-09-30 | ¥21m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | ¥4m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | ¥4m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | ¥4m |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥69.8bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥22.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥69.8bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥22.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥3.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥3.1bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥3.1bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥111.5bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥38.1bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥111.5bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥38.1bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥24m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥8m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥4.6bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥4.6bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥1.97T |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥703.6bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥1.97T |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥703.5bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥243m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥92m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥676.8bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥676.8bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥631.3bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥226.7bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥226.7bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥212.9bn |
| —segment total | revenue | 2023-01-01 → 2023-09-30 | ¥2.16T |
| —segment total | revenue | 2023-07-01 → 2023-09-30 | ¥763.8bn |
| —segment total | revenue external | 2023-01-01 → 2023-09-30 | ¥2.16T |
| —segment total | revenue external | 2023-07-01 → 2023-09-30 | ¥763.7bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥267m |
| —segment total | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥100m |
| —segment total | segment profit | 2023-01-01 → 2023-09-30 | ¥694.6bn |
| —segment total | segment profit | 2023-01-01 → 2023-09-30 | ¥694.6bn |
| —segment total | segment profit | 2023-01-01 → 2023-09-30 | ¥649.9bn |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | ¥231.4bn |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | ¥231.4bn |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | ¥217.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-01-01 → 2022-09-30 | ¥8.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-07-01 → 2022-09-30 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-01-01 → 2022-09-30 | ¥1.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-07-01 → 2022-09-30 | ¥440m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥6.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥643m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-09-30 | −¥24.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-09-30 | −¥24.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-09-30 | −¥22.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | −¥8.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | −¥8.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-07-01 → 2022-09-30 | −¥10.1bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-09-30 | −¥7.1bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥721m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-09-30 | −¥7.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥721m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥48m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥48m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-09-30 | −¥48m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥1m |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥59.7bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥20.4bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥59.7bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥20.4bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥7.3bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥7.3bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥7.3bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E00492-000Pharmaceuticalsreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥112.8bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥39.3bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥112.8bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥39.3bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥722m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥409m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥409m |
| jpcrp040300-q3r_E00492-000Processed Foodreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥306m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥1.83T |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥681.7bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥1.83T |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥681.6bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥215m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥77m |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥653.5bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥653.5bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥594.1bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥228.3bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥228.3bn |
| jpcrp040300-q3r_E00492-000Tobaccoreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥203.7bn |
| —segment total | revenue | 2022-01-01 → 2022-09-30 | ¥2.01T |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥741.4bn |
| —segment total | revenue external | 2022-01-01 → 2022-09-30 | ¥2.01T |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥741.3bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥215m |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥78m |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥662.6bn |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥662.6bn |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥602.0bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥231.1bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥231.1bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥206.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,098
| Item | Context | Value | Unit |
|---|---|---|---|
| Adjustment items income IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 13166000000 | JPY |
| Adjustment items income IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Adjustment items income IFRS | CurrentYTDDuration | 14544000000 | JPY |
| Adjustment items costs IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 1038000000 | JPY |
| Adjustment items costs IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Adjustment items costs IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 5000000 | JPY |
| Adjustment items costs IFRS | CurrentYTDDuration_ReportableSegmentsMember | 1043000000 | JPY |
| Adjustment items costs IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 972000000 | JPY |
| Adjustment items costs IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Adjustment items costs IFRS | CurrentYTDDuration | 2015000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 631276000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 13118000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 5499000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 649892000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -18067000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | 21000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 631847000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 29654000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 75292000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 586209000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 681579000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 20364000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 39337000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 741280000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 440000000 | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1QuarterDuration | 741720000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 77000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 0 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 78000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 643000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -721000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration | － | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 681656000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 20364000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 39337000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 741358000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1083000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -721000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration | 741720000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 228332000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 2402000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q3r_E00492-000ProcessedFoodReportableSegmentMember | 409000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 231143000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -8169000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -1000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration | 222973000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E00492-000TobaccoReportableSegmentMember | 703487000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q3r_E00492-000PharmaceuticalsReportableSegmentMember | 22148000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |